Marked Response to Nab-Paclitaxel in Advanced Neuroendocrine Carcinoma of Nasal Sinuses: A Case Report
Introduction: Sinonasal neuroendocrine carcinomas (SNECs) are a very rare and high-grade malignant epithelial neoplasm that is usually associated with a poor prognosis.
Aim(s): The optimal regimen for second and subsequent lines of chemotherapy for the treatment of SNECs remains unknown.
Materials and methods: This report describes a 50-year-old male patient with advanced sinonasal large-cell NEC (LCNEC) was treated with albumin-bound paclitaxel-based (nab-paclitaxel) regimens every 3 weeks as third-line chemotherapy.
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.